Kanaoka, Kensuke
Sumikawa, Hiromitsu
Oyamada, Shunsuke
Tamiya, Akihiro
Inagaki, Yuji
Taniguchi, Yoshihiko
Nakao, Keiko
Matsuda, Yoshinobu
Okishio, Kyoichi
Funding for this research was provided by:
The Osaka Medical Research for Intractable Diseases
Article History
Received: 9 June 2023
Accepted: 1 September 2023
First Online: 6 September 2023
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the National Hospital Organization Kinki-Chuo Chest Medical Center (Institutional Review Board number 2022–121). The ethics committee of the National Hospital Organization Kinki-Chuo Chest Medical Center waived the need for informed consent because the data were collected retrospectively and anonymized.
: Not applicable.
: Dr. Kanaoka received personal fees from AstraZeneca outside the submitted work. Dr. Oyamada received honoraria from Chugai Co. Dr. Tamiya received grants from AstraZeneca, Beigene, and Daiichi-Sankyo, and personal fees from Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, MSD, Taiho, Pfizer, Takeda Pharmaceutical, Nihon Kayaku, Novartis, Merck Biopharma, and Thermo Fisher Scientific outside the submitted work. Dr. Inagaki received personal fees from AstraZeneca, Chugai, Chugaiigakusya, and Pfizer outside the submitted work. Dr. Taniguchi received personal fees from Chugai Pharmaceutical, Ono Pharmaceutical, and AstraZeneca outside the submitted work. The remaining authors declare no conflicts of interest.